ARDC Research Link Australia

ORCID Profile
Orcid icon. 0000-0002-1099-7401

Current Organisations
Institute of Research in Astrophysics and Planetology , Queen Mary University of London , University of Oxford

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.

Publications

Publication

The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Publisher: Elsevier BV

Date: 2021

DOI: 10.1016/J.KINT.2020.10.012

Publication

NEW PERSPECTIVE ON GALAXY OUTFLOWS FROM THE FIRST DETECTION OF BOTH INTRINSIC AND TRAVERSE METAL-LINE ABSORPTION

Publisher: American Astronomical Society

Date: 18-08-2014

DOI: 10.1088/2041-8205/792/1/L12

Publication

What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?

Publisher: Springer Science and Business Media LLC

Date: 29-04-2015

DOI: 10.1186/S12882-015-0054-0

Publication

Optimisation of Perioperative Cardiovascular Management to Improve Surgical Outcome II (OPTIMISE II) trial: study protocol for a multicentre international trial of cardiac output-guided fluid therapy

Publisher: BMJ

Date: 2019

DOI: 10.1136/BMJOPEN-2018-023455

Abstract: Postoperative morbidity and mortality in older patients with comorbidities undergoing gastrointestinal surgery are a major burden on healthcare systems. Infections after surgery are common in such patients, prolonging hospitalisation and reducing postoperative short-term and long-term survival. Optimal management of perioperative intravenous fluids and inotropic drugs may reduce infection rates and improve outcomes from surgery. Previous small trials of cardiac-output-guided haemodynamic therapy algorithms suggested a modest reduction in postoperative morbidity. A large definitive trial is needed to confirm or refute this and inform widespread clinical practice. The Optimisation of Perioperative Cardiovascular Management to Improve Surgical Outcome II (OPTIMISE II) trial is a multicentre, international, parallel group, open, randomised controlled trial. 2502 high-risk patients undergoing major elective gastrointestinal surgery will be randomly allocated in a 1:1 ratio using minimisation to minimally invasive cardiac output monitoring to guide protocolised administration of intravenous fluid combined with low-dose inotrope infusion, or usual care. The trial intervention will be carried out during and for 4 hours after surgery. The primary outcome is postoperative infection of Clavien-Dindo grade II or higher within 30 days of randomisation. Participants and those delivering the intervention will not be blinded to treatment allocation however, outcome assessors will be blinded when feasible. Participant recruitment started in January 2017 and is scheduled to last 3 years, within 50 hospitals worldwide. The OPTIMISE II trial has been approved by the UK National Research Ethics Service and has been approved by responsible ethics committees in all participating countries. The findings will be disseminated through publication in a widely accessible peer-reviewed scientific journal. ISRCTN39653756 .

Publication